CDNA - CareDx, Inc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
34.80
-0.81 (-2.27%)
As of 1:52PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close35.61
Open35.94
Bid34.67 x 1200
Ask34.82 x 1100
Day's Range34.44 - 36.60
52 Week Range11.80 - 40.50
Volume184,943
Avg. Volume836,268
Market Cap1.409B
Beta (3Y Monthly)0.78
PE Ratio (TTM)N/A
EPS (TTM)-1.17
Earnings DateAug 8, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.40
Trade prices are not sourced from all markets
  • Hedge Funds Have Never Been This Bullish On CareDx, Inc. (CDNA)
    Insider Monkey7 days ago

    Hedge Funds Have Never Been This Bullish On CareDx, Inc. (CDNA)

    At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of March 31. In this […]

  • GlobeNewswire16 days ago

    CareDx to Participate in Upcoming Conferences

    BRISBANE, Calif., June 10, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development and commercialization of.

  • Is CareDx, Inc (NASDAQ:CDNA) Trading At A 41% Discount?
    Simply Wall St.23 days ago

    Is CareDx, Inc (NASDAQ:CDNA) Trading At A 41% Discount?

    How far off is CareDx, Inc (NASDAQ:CDNA) from its intrinsic value? Using the most recent financial data, we'll take a...

  • GlobeNewswire28 days ago

    CareDx Announces KidneyCare and Showcases Leadership in Transplantation at ATC

    BRISBANE, Calif., May 29, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of CDNA earnings conference call or presentation 8-May-19 8:30pm GMT

    Q1 2019 CareDx Inc Earnings Call

  • GlobeNewswirelast month

    CareDx applauds HHS Report on Cost Savings of Lifetime Immunosuppressive Drug Coverage for Transplant Patients

    CareDx, Inc. (CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, applauds the Department of Health and Human Services for releasing a report highlighting the cost savings of lifetime immunosuppressive drug coverage for transplant patients. CareDx is dedicated to improving the long-term health outcomes of transplant recipients. A critical part of protecting a donated kidney is appropriate dosage of immunosuppressant drugs for the life of the recipient, treatment financially out of reach for many individuals without insurance coverage.

  • Here's Why CareDx Stock Is Rising Today
    Motley Fool2 months ago

    Here's Why CareDx Stock Is Rising Today

    The transplant diagnostic service provider took some important steps forward in the first quarter.

  • CareDx, Inc (CDNA) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    CareDx, Inc (CDNA) Q1 2019 Earnings Call Transcript

    CDNA earnings call for the period ending March 31, 2019.

  • CareDx (CDNA) Q1 Earnings and Revenues Top Estimates
    Zacks2 months ago

    CareDx (CDNA) Q1 Earnings and Revenues Top Estimates

    CareDx (CDNA) delivered earnings and revenue surprises of 350.00% and 7.07%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    CareDx: 1Q Earnings Snapshot

    On a per-share basis, the Brisbane, California-based company said it had a loss of 18 cents. Earnings, adjusted for stock option expense and non-recurring costs, came to 5 cents per share. The results ...

  • GlobeNewswire2 months ago

    CareDx Reports First Quarter 2019 Results

    BRISBANE, Calif., May 08, 2019 -- CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically.

  • GlobeNewswire2 months ago

    CareDx’s AlloSeq cfDNA and QTYPE Solutions Featured at EFI 2019

    BRISBANE, Calif., May 07, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of.

  • The CareDx (NASDAQ:CDNA) Share Price Is Up 580% And Shareholders Are Delighted
    Simply Wall St.2 months ago

    The CareDx (NASDAQ:CDNA) Share Price Is Up 580% And Shareholders Are Delighted

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Investing can be hard but the potential fo an individual stock to pay off big time inspires us...

  • GlobeNewswire2 months ago

    AlloMap In-Network with Anthem Blue Cross

    BRISBANE, Calif., May 03, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically.

  • GlobeNewswire2 months ago

    CareDx Adds iBox Technology, Next Step Towards Artificial Intelligence in Transplant Care

    CareDx, Inc. (CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced a partnership with Cibiltech, a French MedTech company that develops AI-based products for predictive medicine, to commercialize Predigraft. Predigraft is a data analysis tool that provides an early prediction of an individual’s risk of allograft rejection and transplant loss. It was developed from Cibiltech’s proprietary software algorithm called iBox, which is built off the outcomes data from tens of thousands of transplant patients.

  • CareDx (CDNA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks2 months ago

    CareDx (CDNA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire2 months ago

    CareDx Agrees to Acquire OTTR Complete Transplant Management

    CareDx, Inc. (CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients,  today announced it has agreed to acquire OTTR Complete Transplant Management (“OTTR”), the leading provider of organ transplant patient tracking software. OTTR provides comprehensive solutions for transplant patient management, which are currently used in over 60 leading transplant centers in the US.

  • GlobeNewswire2 months ago

    CareDx to Announce First Quarter 2019 Financial Results on May 8th, 2019

    BRISBANE, Calif., April 23, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on creating diagnostic solutions for organ transplant patients,.

  • Breakeven On The Horizon For CareDx, Inc (NASDAQ:CDNA)
    Simply Wall St.3 months ago

    Breakeven On The Horizon For CareDx, Inc (NASDAQ:CDNA)

    CareDx, Inc's (NASDAQ:CDNA): CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic solutions for transplant patients worldwide...

  • GlobeNewswire3 months ago

    CareDx Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients

    CareDx, Inc. (CDNA), a leading molecular diagnostics company focused on creating diagnostic solutions for organ transplant patients, has filed a second lawsuit against Natera, Inc. in the United States District Court for Delaware. In this suit, CareDx alleges that Natera’s comparisons of its kidney transplant technology to CareDx’s AlloSure technology are based on numerous unscientific, unreliable, and inappropriate conclusions, and are therefore misleading.

  • GlobeNewswire3 months ago

    Cutting-Edge HeartCare and AlloMap Solutions Featured at ISHLT 2019

    BRISBANE, Calif., April 03, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of.

  • A new lawsuit involving Stanford and Sequoia Capital highlights fights to come over cell-free DNA testing
    TechCrunch3 months ago

    A new lawsuit involving Stanford and Sequoia Capital highlights fights to come over cell-free DNA testing

    This morning, a publicly traded transplant diagnostics company called CareDx,along with Stanford University, sued another publicly traded genetic testingcompany, Natera, for patent infringement

  • GlobeNewswire3 months ago

    CareDx Files Patent Infringement Lawsuit Against Natera

    CareDx, Inc. (CDNA), a leading molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it has filed a patent infringement suit against Natera, Inc., in the United States District Court for Delaware.  CareDx is asserting U.S. Patent Nos. 9,845,497 and 8,703,652, that are exclusively licensed to CareDx from Stanford University.  Stanford is joined in the suit as a necessary party because it is the registered owner of these patents.  These patents cover non-invasive monitoring of organ transplant rejection through cell-free DNA analysis.